 JUPITER, Fla., March 22, 2021 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, we, us, our, or the Company NASDAQ: DYAI, a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company is expanding its partnership with South Koreas Medytox, Inc. Medytox, a global biopharmaceutical company with sales in approximately 60 countries. Dyadic and Medytox will co-develop C1 manufactured COVID-19 vaccines andor boosters, which will, if successful, be used to immunize people against two or more of the current and future COVID-19 variants. This project can provide dedicated local supply, to help combat COVID-19, in this region of the world. 